Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s share price traded up 12.9% on Wednesday . The stock traded as high as C$1.76 and last traded at C$1.75. 62,156 shares changed hands during mid-day trading, a decline of 49% from the average session volume of 122,649 shares. The stock had previously closed at C$1.55.
Medicenna Therapeutics Stock Up 21.3 %
The company has a market cap of C$130.92 million, a PE ratio of -6.74 and a beta of 1.16. The stock has a 50-day moving average of C$1.45 and a 200-day moving average of C$0.79. The company has a quick ratio of 4.65, a current ratio of 5.00 and a debt-to-equity ratio of 0.06.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
See Also
- Five stocks we like better than Medicenna Therapeutics
- Industrial Products Stocks Investing
- High-Yield Texas Instruments Could Hit New Highs Soon
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- The “How” and “Why” of Investing in 5G Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
